Drug Profile
VS 4718
Alternative Names: VS-4718Latest Information Update: 11 May 2018
Price :
$50
*
At a glance
- Originator The Scripps Research Institute
- Developer Verastem
- Class Antineoplastics; Small molecules
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Pancreatic cancer; Solid tumours
Most Recent Events
- 03 May 2018 Verastem is now operating as Verastem Oncology
- 01 Jun 2017 Verastem terminates a phase I trial in Solid tumours (Metastatic disease, Late-stage disease) in USA due to sponsor's decision to deprioritise the program(NCT01849744)
- 23 Mar 2017 Discontinued - Phase-I for Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in USA (PO)